Cargando…
Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience
Imatinib treatment in metastatic or inoperable gastrointestinal stromal tumours (GIST) has shifted the paradigm of treatment of this disease. Successful clinical trials of imatinib led to rapid regulatory approval and, in England and Wales, National Institute for Health and Clinical Excellence (NICE...
Autores principales: | Azribi, F, Razak, ARA, Dildey, P, Adam, J, Wilsdon, J, Verrill, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223987/ https://www.ncbi.nlm.nih.gov/pubmed/22276023 http://dx.doi.org/10.3332/ecancer.2010.162 |
Ejemplares similares
-
Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010) -
Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?
por: Giraud, Eline L., et al.
Publicado: (2023) -
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017) -
Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era
por: van der Graaf, W. T. A., et al.
Publicado: (2018) -
Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
por: Date, Ravindra S, et al.
Publicado: (2008)